Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04104438 · ClinicalTrials.gov registry record · Phase 4
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
A Phase 4 study of Asses Immunosuppression Modulation on Renal Recovery Post LT, sponsored by Fady M Kaldas, M.D., F.A.C.S..
- Completed
- Registry status
- Phase 4
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT04104438: Completed Phase 4 study of Asses Immunosuppression Modulation on Renal Recovery Post LT, sponsored by Fady M Kaldas, M.D., F.A.C.S..
NCT04104438 is a Phase 4 study of Asses Immunosuppression Modulation on Renal Recovery Post LT that has completed, run by Fady M Kaldas, M.D., F.A.C.S.. The registered enrollment target is 71 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04104438, a Phase 4 study of Asses Immunosuppression Modulation on Renal Recovery Post LT, has completed, sponsored by Fady M Kaldas, M.D., F.A.C.S..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard immunosuppressive medications after your liver transplant. Also the study will assess how safe the new combination of immunosuppressive medicines are and if there are any changes in how your kidneys work after taking these medicines.
Primary Outcome
Assessment of dialysis independence (patients no longer requiring dialysis post LT)
Conditions Studied
Interventions
- DRUG Basiliximab 20 MG
Study Locations (1)
California
- UCLA Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 4 |
What the finished NCT04104438 record still lists
NCT04104438 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Asses Immunosuppression Modulation on Renal Recovery Post LT appearing as the primary indexed condition, and to 1 intervention - of which Basiliximab 20 MG is the first listed.
NCT04104438 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04104438 about?
NCT04104438 is a clinical study titled "Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant". This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard immunosuppressive medications after your liver transplant. Also the study wi...
What is the current status of trial NCT04104438?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 71 participants. The study started on 2021-01-15. Estimated completion is 2024-09-30.
What conditions does trial NCT04104438 study?
This clinical trial studies the following conditions: Asses Immunosuppression Modulation on Renal Recovery Post LT.
What interventions are being tested in trial NCT04104438?
The interventions under investigation include: Basiliximab 20 MG (DRUG).
Who is sponsoring clinical trial NCT04104438?
This trial is sponsored by Fady M Kaldas, M.D., F.A.C.S., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04104438 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04104438's enrollment target sits among peer trials
71 1040th of 2000 higher than 959 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI